N-Glycan Characterization and the Future of Method Standardization
Protein Metrics is hosting a virtual webinar on March 6, 2024, featuring scientist Jill Kinzer, which will explore the critical role of N-glycan characterization in monoclonal antibody therapeutics, compare glycan profiles of innovator and biosimilar mAbs, discuss their impact on drug efficacy and patient outcomes, and address the urgent need for standardized glycan analysis methods.
Join Protein Metrics for a deep dive into the world of protein therapeutics in the upcoming webinar, N-Glycan Characterization and the Future of Method Standardization. This session will shed light on the critical role of N-glycans in the development and efficacy of monoclonal antibody (mAb) products and the pressing need for standardization in glycan characterization methods.
N-glycans are omnipresent in the Fc region of monoclonal antibody products. Modifications to a glycan profile can impact a protein’s stability/folding, binding affinities, effector functions, clearance rates, and/or immunogenicity. Their characterization is critical to ensuring efficacy and safety in patients. The multitude of glycan characterization methods, each with different levels of sensitivity and reliability, complicates standardization efforts. To tackle this, comparative glycan analysis studies have been conducted, examining various innovator mAbs, their biosimilars, and different characterization techniques for NIST mAb.
Key learnings
- Comparison of innovator anti-TNF⍺ mAbs (Humira®, Remicade®, Simponi Aria®) and trastuzumab biosimilars (Kanjinti®, Ogivri®) with reference drugs.
- Highlighting the impact of glycan differences in mAbs on patient experience.
- Suggesting future standardization approaches for glycan characterization in mAbs.
Jill Kinzer is a scientist at MS Bioworks, a contract proteomics research company based in Ann Arbor, Michigan. During her Ph.D. (Pharmaceutical Sciences, University of Michigan, under Dr. Anna Scwendeman), Jill introduced automation into MS Bioworks’ post-translational modification identification and quantitation workflows. Jill has authored six papers on monoclonal antibody characterization methods and is working on streamlining plate-based proteomics assays.
Event Details
- Date: March 6, 2024
- Time: 9:00 EST
- Format: Virtual
Related
How Bispecific Antibodies Are Changing the Treatment of Complex Diseases
Bispecific antibodies, an advanced form of antibody therapeutics derived from the natural IgG structure, are revolutionizing the treatment of complex and treatment-resistant diseases by enabling simultaneous targeting of two different antigens, thereby expanding the possibilities of personalized immunotherapy in a rapidly growing market.
Mass Spectrometry Symposium 2023
The Mass Spectrometry Symposium 2023, held September 5-8 at the Renaissance Chicago Downtown Hotel, focuses on the practical application of mass spectrometry in biotechnology, highlighting its role in biopharmaceutical discovery, development, and commercialization, with Protein Metrics participating in the event.
What are monoclonal antibodies? | Dotmatics
Monoclonal antibodies (MABs) are identical antibodies produced from a single immune cell designed to specifically target antigens, primarily used as therapeutic agents to treat diseases such as cancers and autoimmune disorders by neutralizing disease-related proteins with high specificity and flexible administration methods.
The Future of Biologics Discovery
The article discusses the transformative potential of biologics in medicine, highlighting that biologics discovery involves designing complex, biologically-derived drugs like antibodies and gene therapies, which require sophisticated technology and controlled conditions due to their sensitivity and complexity, while also addressing challenges such as workflow complexity, high costs, and safety concerns in the development process.
Dotmatics Luma Lab Connect Unlocks the Untapped Value of Lab Instrument Data to Accelerate Scientific R&D Decision-Making
Dotmatics has launched Luma™ Lab Connect, a low-code cloud solution that automatically centralizes, parses, and models fragmented lab instrument data from diverse sources to enhance data accuracy, streamline workflows, and accelerate scientific R&D decision-making by enabling deeper analysis and AI-ready insights across experiments.
Protein Metrics by Dotmatics
Protein Metrics by Dotmatics is a vendor-neutral, compliance-ready software platform trusted by over 200 biopharmaceutical companies and 300 academic institutions that accelerates protein characterization and proteomic analysis through scalable, automated, and templated workflows enabling reproducible biotherapeutic reporting, deep data insights, seamless transition between non-GxP and GxP environments, and efficient knowledge sharing across discovery and regulated settings.